The high price of the new hepatitis C virus drugs

JAMA Internal Medicine

Volumn 174, Issue 7, 2014, Pages 1172-

  Steinbrook, Robert ^a   Redberg, Rita F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SIMEPREVIR; SOFOSBUVIR;

DRUG COST; DRUG INDUSTRY; HEALTH CARE SYSTEM; HEPATITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER FAILURE; NOTE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84904131013     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.2135     Document Type: Note

References (6)

1. Ollendorf DA, Tice JA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection [published online May 5, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2014. 2151.
2. Tice JA, Ollendorf DA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: final report (April 15, 2014). http://www.ctaf.org/assessments/ treatments-hepatitis-c. Accessed April 16, 2014.
3. Centers for Disease Control and Prevention. Hepatitis C information for health professionals. http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed April 23, 2014.
4. World Health Organization. Hepatitis C fact sheet No. 164 (2011). http://www.hcv-ka.de/pdf/HepC%20WHO%20fact%20sheet%20164.pdf. Accessed April 17, 2014.
5. Pollack A. Gilead revenue soars on hepatitis C drug. New York Times. http://www.nytimes.com/2014/04/23/your-money/gilead-revenue-soars-on-hepatitis- c-drug.html. Accessed April 23, 2014.
6. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58(7):928-936.